Connect with us

Hi, what are you looking for?

Thursday, Jun 30, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Business

Numinus develops in-house tests to detect compounds in psychedelic mushrooms

The methods will be available as part of third-party client services

Numinus develops in-house tests to detect compounds in psychedelic mushrooms
Photo via Numinus

As Canada inches toward one day approving the regulated sale and use of psychedelic substances, Numinus Wellness Inc. (TSX-V: NUMI) says it’s developed testing to screen for various compounds found in magic mushrooms.

On Monday, the Vancouver, B.C.-based company said the proprietary methods will be available as part of its third-party client services, and used for evidence-based conversations with regulators.

Among other areas, Numinus’s Bioscience division is developing testing for the fruiting bodies, extracts and derivatives of psilocybe mushrooms. According to a statement, the lab has validated methods for active constituent compounds, alongside required testing for contaminants and residues.

The psilocybe screen includes psilocybin, psilocin, baeocystin, norbaeocystin, tryptophan, norpsilocin and aeruginascin — which Numinus says represents the most well-defined alkaloids for the mushroom type.

“The testing we’ve developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry,” says Sharan Sidhu, science officer and general manager at Numinus.

“Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products,” she said in the statement.

The company adds that it’s developed a psychedelic toxicity test that includes nephrotoxic (affecting the kidney) and hepatotoxic (affecting the liver) compounds.

Read more: Numinus set to open Canada’s first psychedelics neurology centre

While the tests have been developed for the industry, Numinus says they can also be used by healthcare providers in poison control responses. Toxicity scans are completed using the Orbitrap, a high-resolution mass-spectrometry instrument.

Founder and CEO Payton Nyquvest says these in-house methods show’s his company’s commitment to strengthen regulatory confidence in these products.

The firm says it’s research team has identified over 260 compounds so far, many of them characterized for the first time in psychedelic mushrooms. Other than psilocybin, the company is also developing testing capabilities for ketamine, LSD, mescaline, DMT and MDMA.

Numinus stock traded at $0.61 Monday on the TSX Venture Exchange.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

nick@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe